💼 SyVento BioTech leads the Polish market as the first mRNA FlexFactory in Europe, equipped with advanced automation.
🛠️ The facility supports scalable mRNA therapies from lab to commercial production. It enhances efficiency and compliance.
🎉 A celebration for this GMP-certified facility is planned for May 2025.
Introduction:
Cytiva has introduced its innovative mRNA manufacturing platform, the FlexFactory, to Poland. This deployment marks a significant advancement in mRNA therapy production, emphasizing efficiency and high-quality standards, catering to the growing demand for cutting-edge medical therapies in Europe.
- SyVento BioTech has opened a new mRNA manufacturing facility, the first of its kind in Poland, integrating the FlexFactory delivered by Cytiva.
- The facility covers over 7,000 m2 and includes specialized labs, production areas, and office spaces designed for efficient operation.
- With the installation of the Historian automation system, this FlexFactory sets a new standard for data integrity and compliance in manufacturing processes.
- The FlexFactory serves as a versatile platform that supports the production of both large and personalized mRNA therapies, providing a comprehensive solution from lab-scale to commercial production.
- SyVento BioTech is set to celebrate the certification of its GMP-compliant facility in May 2025, solidifying its commitment to high manufacturing standards.
Conclusion:
The introduction of Cytiva’s FlexFactory in Poland positions SyVento BioTech at the forefront of mRNA therapeutics in Europe, enabling enhanced access to new therapies for patients. This facility not only exemplifies advancements in production technology but also indicates a shifting landscape towards efficient and reliable bio-manufacturing practices, creating opportunities for future innovations in healthcare.
